March 10 (Reuters) - PMGC Holdings Inc ELAB.O:
NORTHSTRIVE BIOSCIENCES INC. SCHEDULES PRE-IND MEETING WITH FDA FOR EL-22, AN OBESITY THERAPY TARGETING FAT LOSS AND MUSCLE PRESERVATION IN COMBINATION WITH GLP-1
NORTHSTRIVE BIOSCIENCES : SCHEDULED A PRE-IND MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION FOR APRIL 23, 2025
Source text: nGNX7B0PkG
Further company coverage: ELAB.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。